You are here

  • Home
  • Archive
  • Volume 8, Issue 2
  • Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Article info

Article menu
XML
Clinical/translational cancer immunotherapy
Original research
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity

Authors

  • Tae Hee Hong Samsung Genome Institute, Samsung Medical Center, Seoul, Korea Department of Digital Health, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Hongui Cha Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Joon Ho Shim Samsung Genome Institute, Samsung Medical Center, Seoul, Korea Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Boram Lee Samsung Genome Institute, Samsung Medical Center, Seoul, Korea Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Jongsuk Chung Samsung Genome Institute, Samsung Medical Center, Seoul, Korea PubMed articlesGoogle scholar articles
  • Chung Lee GENINUS Inc, Seoul, Korea PubMed articlesGoogle scholar articles
  • Nayoung K D Kim GENINUS Inc, Seoul, Korea PubMed articlesGoogle scholar articles
  • Yoon-La Choi Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea Department of Pathology and Translational Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Soohyun Hwang Department of Pathology and Translational Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Yoomi Lee Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Sehhoon Park Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Hyun Ae Jung Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Ji-Yeon Kim Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Yeon Hee Park Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Jong-Mu Sun Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Jin Seok Ahn Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Myung-Ju Ahn Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Keunchil Park Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea PubMed articlesGoogle scholar articles
  • Se-Hoon Lee Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea PubMed articlesGoogle scholar articles
  • Woong-Yang Park Samsung Genome Institute, Samsung Medical Center, Seoul, Korea Department of Digital Health, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea Department of Health Science and Technology, Samsung Advanced Institute of Health Science and Technology, Sungkyunkwan University, Seoul, Korea GENINUS Inc, Seoul, Korea Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea PubMed articlesGoogle scholar articles

Citation

Hong TH, Cha H, Shim JH, et al
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
Journal for ImmunoTherapy of Cancer 2020;8:e001199. doi: 10.1136/jitc-2020-001199
Online issue publication 
October 19, 2020

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY. Published by BMJ. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.